This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: K51.9 | Special Copayment Reduction: V131 (severe intractable disease, 5 years) |
| B. Synonyms | None (unspecified UC, ulcerative colitis with classification undetermined) |
| C. Adult onset | Adult onset possible — used as a provisional classification code before initial diagnosis or additional testing; reclassification to the appropriate code (K51.0–K51.8) after confirmed diagnosis is the rule |
| 1. History | See main text |
| 2. Causes | See main text |
| 3. Genetics | See main text |
| 4. General epidemiology | See main text |
| 5. Pathophysiology | See main text |
| 6. Symptoms | See main text |
| 7. Signs | See main text |
| 8. Screening | See main text |
| 9. Diagnosis | See main text |
| 10. Treatment | See main text |
| 11. Prognosis | See main text |
| 12. Prevention | See main text |
| 13. References | See main text |
K51.9 (ulcerative colitis, unspecified) of ICD-10 is a code used when a diagnosis of UC has been made but the extent and characteristics of the lesions have not been sufficiently confirmed and a specific classification has not been made. The clinical description history of UC began with Wilks in 1859, but improvement in diagnostic accuracy went hand in hand with the development of endoscopic technology. In the past, diagnosis was made with only a rigid proctoscope or barium enema radiography, so it was difficult to determine the exact extent of lesions, and in this period cases were often recorded simply as 'UC' without detailed classification.
At present, the K51.9 code is mainly used provisionally at the initial diagnostic stage, or when UC is strongly suspected clinically but total colonoscopy has not yet been performed. Examples include the pre-endoscopy management stage on admission for acute severe UC, or prescriptions made at the first gastroenterology outpatient visit with total colonoscopy scheduled. After final endoscopic and histopathological confirmation, the rule is to reclassify into the appropriate code among K51.0–K51.8.
The cause of K51.9 is the same as that of ordinary UC. It arises from a complex interaction of genetic predisposition (HLA-DR2, IL-10, etc.), gut microbial dysbiosis, mucosal immune dysregulation (Th2/Th9 skewing), and environmental factors (smoking, NSAIDs, antibiotics, diet, stress). K51.9 is a diagnostic classification code, not a disease with a separate etiology. Therefore, the 'unspecified' classification does not mean an unknown etiology but an unclassified state of lesion extent or clinical characteristics. Total colonoscopy and biopsy for diagnostic confirmation should be performed promptly.
The genetic basis of K51.9 is the same as that of typical UC. HLA-DR2 (DRB1*15:02) is the strongest genetic risk factor across UC, and more than 200 susceptibility loci are associated, including IL-10 receptor, ECM1, HNF4α, IL-23R, LAMB1, and CDH1. In relation to therapeutic drug metabolism, TPMT and NUDT15 gene polymorphism testing is recommended before azathioprine administration. In particular, the frequency of the NUDT15 R139C variant is high in East Asians including Koreans, so genetic testing before azathioprine administration is clinically important.
The exact epidemiology of patients classified as K51.9 is difficult to determine. Because this code is mainly used as a provisional classification early in diagnosis, it is eventually converted to another detailed K51 code. Among patients registered as K51.9 in health insurance claims data, a considerable number are cases that were not reclassified after endoscopy. Applying overall UC epidemiology, the UC prevalence in Korea has increased to 30/100,000 or more (as of the 2020s). Patients registered as K51.9 in the first year of diagnosis should be converted to the appropriate classification through prompt total colonoscopy.
The pathophysiology of unspecified UC is the same as that of typical UC. A continuous process of mucosal barrier damage, exposure to gut microbial antigens, abnormal activation of innate immunity (dendritic cells, macrophages) and adaptive immunity (Th2, Th9, Th17), neutrophil infiltration, and mucosal ulcer formation is expressed in the colonic mucosa. The 'unspecified' classification does not mean an unknown pathophysiology; it reflects a state in which the pathological mechanisms of typical UC are operating but the clinical and endoscopic characteristics have not yet been fully identified.
The clinical symptoms of K51.9 follow the general symptoms of UC. Bloody diarrhea, mucoid stool, abdominal pain (location varies with the extent of involvement), and urgency are the main symptoms. Systemic symptoms (fever, weight loss, fatigue, anemia) appear depending on disease activity. Extraintestinal symptoms (arthralgia, skin symptoms, ocular symptoms, PSC) may also occur. Early in the diagnosis it is difficult to predict the extent of involvement from symptoms alone, so endoscopy should be performed promptly.
Physical findings vary with extent of involvement and disease activity. The location of abdominal tenderness indirectly suggests the involved colonic segment. In severe UC, tachycardia, fever, pallor, and hypotension may appear. On blood tests, CRP, ESR, white blood cell count, and platelet count are elevated, and anemia and hypoalbuminemia appear depending on activity. Fecal calprotectin is a sensitive noninvasive marker of active intestinal inflammation. Stool culture is performed to exclude infectious colitis.
Screening of the general population is not recommended. In patients complaining of bloody diarrhea, mucoid stool, and abdominal pain, colonoscopy is performed if fecal calprotectin is >150 μg/g. When acute severe UC is suspected (bloody diarrhea >6 times/day, with fever, tachycardia, anemia), immediate inpatient evaluation is needed. After provisional classification as K51.9, total colonoscopy is performed promptly to confirm the extent of lesions and histopathology and reclassify into the appropriate code.
K51.9 is used as a provisional code, and total colonoscopy and multi-site biopsy are essential for diagnostic confirmation. On endoscopy, mucosal inflammation distributed continuously starting from the rectum (erythema, loss of vascular pattern, spontaneous bleeding, granular mucosa, ulcers) is confirmed, and the upper boundary of the lesion is accurately recorded. If crypt architectural distortion, basal plasmacytosis, and neutrophil infiltration are confirmed on histopathology, this supports the diagnosis of UC. Crohn disease (skip lesions, small bowel involvement, perianal lesions, transmural granulomas) and infectious colitis (stool culture) must be excluded. Reclassify into K51.0–K51.8 according to endoscopic and histopathological results.
Treatment of UC provisionally classified as K51.9 is started immediately according to clinical severity. Even before confirmed diagnosis, mesalazine treatment can be started when UC is strongly suspected clinically and infectious colitis has been excluded. When acute severe UC is suspected, intravenous steroids are given after admission while exclusion of infection, such as Clostridioides difficile toxin testing, is carried out at the same time. After the final diagnostic classification, the optimal treatment plan according to the extent of lesions (whether to combine topical agents, indications for immunosuppressants or biologics, etc.) is established.
The prognosis of K51.9 is determined by the UC phenotype finally classified. Shortening the provisional classification period, confirming the diagnosis promptly, and starting appropriate treatment is the key to improving prognosis. Delay in diagnosis or treatment raises the risk of severe complications (toxic megacolon, intestinal perforation, bleeding). Mesalazine maintenance treatment after remission induction and regular follow-up endoscopy determine the long-term prognosis.
Early confirmed diagnosis and establishment of an appropriate treatment plan are the key to prevention strategy. In patients provisionally classified as K51.9, total colonoscopy should be performed as soon as possible (within 2~4 weeks) to confirm the extent of lesions. After diagnosis is confirmed, reclassify into the appropriate code and establish the optimal treatment plan according to the extent of lesions. After diagnostic confirmation, the prevention strategies of typical UC (mesalazine maintenance, colorectal cancer surveillance endoscopy, management of relapse triggers) are applied identically.